1
|
Jung L, Huwer SI, Taran FA, Unger C, Müller C, Solomayer EF, Juhasz-Böss I, Neubauer J. Diagnostic performance of additional imaging tests for staging purposes in a bicentric German series of low-risk early breast cancer patients. Arch Gynecol Obstet 2024; 309:1475-1481. [PMID: 37676317 PMCID: PMC10894132 DOI: 10.1007/s00404-023-07169-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 07/20/2023] [Indexed: 09/08/2023]
Abstract
PURPOSE Low-risk early breast cancer rarely leads to the development of metastatic disease, and in these patients, additional imaging test is controversial. The aim of our study was to evaluate the conventional staging procedures in a bicentric German series of low-risk breast carcinoma patients. METHODS Retrospective evaluation of all patients diagnosed with early, low-risk breast cancer at Saarland University Hospital and Freiburg University Hospital in 2017 was performed. Clinical patient characteristics, the number and type of additional imaging examinations, follow-up examinations, and results were evaluated. The detection rate of metastases and the rate of false-positive findings were analyzed. RESULTS A total of 203 patients were included, with all patients received at least one additional imaging test. Initially, a total of 562 additional imaging examinations were performed: 166 chest X-rays, 169 upper abdominal ultrasounds, 199 bone scans, 27 computer tomographies (CT) chest and abdomen, and 1 CT abdomen. 6.8% of patients had abnormal findings reported, requiring 38 additional imaging examinations. One patient (0.5%) was found to have bone metastases. The rate of false-positive findings in the performed additional imaging procedures was 6.6%. CONCLUSION Metastatic disease was detected in one of 203 patients with low-risk early breast cancer. A total of 562 examinations and additional 38 follow-up examinations were performed without detection of metastasis (this corresponds to approximately 3 examinations/patient). The rate of false-positive findings was 6.6%. The performance of additional imaging procedures for detection of distant metastases should be critically reconsidered in patients with low-risk early breast cancer.
Collapse
Affiliation(s)
- Lisa Jung
- Department of Obstetrics & Gynecology at the Medical Center-University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
- Department of Obstetrics and Gynecology at the Medical Center, University of Saarland, Homburg, Germany.
| | - Sarah Isabelle Huwer
- Department of Obstetrics & Gynecology at the Medical Center-University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany
- Department of Obstetrics and Gynecology at the Medical Center, University of Saarland, Homburg, Germany
| | - Florin-Andrei Taran
- Department of Obstetrics & Gynecology at the Medical Center-University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany
| | - Clara Unger
- Department of Obstetrics & Gynecology at the Medical Center-University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany
| | - Carolin Müller
- Department of Obstetrics and Gynecology at the Medical Center, University of Saarland, Homburg, Germany
| | - Erich-Franz Solomayer
- Department of Obstetrics and Gynecology at the Medical Center, University of Saarland, Homburg, Germany
| | - Ingolf Juhasz-Böss
- Department of Obstetrics & Gynecology at the Medical Center-University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany
| | - Jakob Neubauer
- Department of Radiology, University Medical Center Freiburg, Freiburg, Germany
| |
Collapse
|
2
|
Unger C, Bronsert P, Michalski K, Bicker A, Juhasz-Böss I. Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82:50-58. [PMID: 35027860 PMCID: PMC8747897 DOI: 10.1055/a-1638-9429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 09/06/2021] [Indexed: 10/28/2022] Open
Abstract
Background Prostate specific membrane antigen (PSMA) is a promising protein for breast cancer patients. It has not only been detected in prostate cancer but is also expressed by tumor cells and the endothelial cells of tumor vessels in breast cancer patients. PSMA plays a role in tumor progression and tumor angiogenesis. For this reason, a number of diagnostic and therapeutic methods to target PSMA have been developed. Method This paper provides a general structured overview of PSMA and its oncogenic potential, with a special focus on its role in breast cancer. This narrative review is based on a selective literature search carried out in PubMed and the library of Freiburg University Clinical Center. The following key words were used for the search: "PSMA", "PSMA and breast cancer", "PSMA PET/CT", "PSMA tumor progression". Relevant articles were explicitly read through, processed, and summarized. Conclusion PSMA could be a new diagnostic and therapeutic alternative, particularly for triple-negative breast cancer. It appears to be a potential predictive and prognostic marker.
Collapse
Affiliation(s)
- Clara Unger
- Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg, Germany
| | - Peter Bronsert
- Institut für Klinische Pathologie, Universitätsklinikum Freiburg, Freiburg, Germany
| | - Kerstin Michalski
- Klinik für Nuklearmedizin, Universitätsklinikum Freiburg, Freiburg, Germany
| | - Anna Bicker
- Klinik für Gynäkologie und Geburtshilfe in den St. Vincentius Kliniken, Karslruhe, Germany
| | - Ingolf Juhasz-Böss
- Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg, Germany
| |
Collapse
|
3
|
Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, Kern F, Schwarz T, Mangold M, Unger C, Dörfler F, Kadler S, Rosowski J, Gürcan K, Uyar-Aydin Z, Frentsch M, Kurth F, Schnatbaum K, Eckey M, Hippenstiel S, Hocke A, Müller MA, Sawitzki B, Miltenyi S, Paul F, Mall MA, Wenschuh H, Voigt S, Drosten C, Lauster R, Lachman N, Sander LE, Corman VM, Röhmel J, Meyer-Arndt L, Thiel A, Giesecke-Thiel C. Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science 2021; 374:eabh1823. [PMID: 34465633 PMCID: PMC10026850 DOI: 10.1126/science.abh1823] [Citation(s) in RCA: 175] [Impact Index Per Article: 58.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The functional relevance of preexisting cross-immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a subject of intense debate. Here, we show that human endemic coronavirus (HCoV)–reactive and SARS-CoV-2–cross-reactive CD4+ T cells are ubiquitous but decrease with age. We identified a universal immunodominant coronavirus-specific spike peptide (S816-830) and demonstrate that preexisting spike- and S816-830–reactive T cells were recruited into immune responses to SARS-CoV-2 infection and their frequency correlated with anti–SARS-CoV-2-S1-IgG antibodies. Spike–cross-reactive T cells were also activated after primary BNT162b2 COVID-19 messenger RNA vaccination and displayed kinetics similar to those of secondary immune responses. Our results highlight the functional contribution of preexisting spike–cross-reactive T cells in SARS-CoV-2 infection and vaccination. Cross-reactive immunity may account for the unexpectedly rapid induction of immunity after primary SARS-CoV-2 immunization and the high rate of asymptomatic or mild COVID-19 disease courses.
Collapse
Affiliation(s)
- Lucie Loyal
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Julian Braun
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Larissa Henze
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Beate Kruse
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Manuela Dingeldey
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Ulf Reimer
- JPT Peptide Technologies GmbH, Berlin, Germany
| | - Florian Kern
- JPT Peptide Technologies GmbH, Berlin, Germany
- Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK
| | - Tatjana Schwarz
- Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Maike Mangold
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Clara Unger
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Friederike Dörfler
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Shirin Kadler
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Jennifer Rosowski
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Kübrah Gürcan
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Zehra Uyar-Aydin
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Marco Frentsch
- Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Therapy-Induced Remodeling in Immuno-Oncology, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Florian Kurth
- Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - Maren Eckey
- JPT Peptide Technologies GmbH, Berlin, Germany
| | - Stefan Hippenstiel
- Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Hocke
- Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Marcel A. Müller
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany
| | - Birgit Sawitzki
- Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | | | - Friedemann Paul
- Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Marcus A. Mall
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- German Center for Lung Research, Associated Partner, Berlin, Germany
| | | | - Sebastian Voigt
- Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany
- Institute for Virology, Universitätsklinikum Essen, Essen, Germany
| | - Christian Drosten
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany
| | - Roland Lauster
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
| | - Nils Lachman
- Institute for Transfusion Medicine, Tissue Typing Laboratory, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Leif-Erik Sander
- Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Victor M. Corman
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany
| | - Jobst Röhmel
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Lil Meyer-Arndt
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology and Experimental Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Thiel
- Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Corresponding author. (A.T.); (C.G.-T.)
| | - Claudia Giesecke-Thiel
- Max Planck Institute for Molecular Genetics, Berlin, Germany
- Corresponding author. (A.T.); (C.G.-T.)
| |
Collapse
|
4
|
Chang O, Bretschneider C, Unger C. 17: Perioperative adverse events by route of surgery in patients undergoing rectovaginal fistula repair in the United States. Am J Obstet Gynecol 2019. [DOI: 10.1016/j.ajog.2019.01.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
5
|
Chang O, Thomas T, Unger C. 04: Embryologic development of the external genitalia as it relates to vaginoplasty for the transgender woman. Am J Obstet Gynecol 2019. [DOI: 10.1016/j.ajog.2019.01.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Takacs FZ, Radosa JC, Linxweiler M, Kasoha M, Bohle RM, Bochen F, Unger C, Solomayer EF, Schick B, Juhasz-Böss I. Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer. Arch Gynecol Obstet 2019; 299:1405-1413. [PMID: 30747329 DOI: 10.1007/s00404-019-05081-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 02/02/2019] [Indexed: 12/11/2022]
Abstract
PURPOSE In previous studies, we have shown that SEC62 has an essential function in cell migration, epithelial-to-mesenchymal transition, and endoplasmic reticulum stress tolerance of cancer cells. SEC62 expression correlated with distant and lymph node metastasis and poor outcome in different cancer entities. In this initial study, we investigated SEC62 expression and its possible role as a prognostic and predictive biomarker in breast cancer (BC). METHODS Formalin-fixed, paraffin-embedded tissue samples of 53 BC patients were analyzed by immunohistochemistry. The immunoreactive score (IRS) according to Remmele and Stegner was evaluated and correlated with clinico-pathological findings and overall survival (OS). RESULTS We found increased SEC62 protein levels in tumor tissue compared to tumor-free tissue samples from the same patients. Tumors with high SEC62 expression (IRS > 8), or containing isolated cells with high SEC62 staining intensity, independent of the IRS, had more frequently distant metastases (48.4% vs. 18.2%; p = 0.024 and 47.4 vs. 6.7%; p = 0.005, respectively). Overall survival was significantly worse in BC patients with high SEC62 expression (SEC62 IRS > 8) (54.8% vs. 81.8%; p = 0.011) and in cases with isolated high-intensity SEC62 staining cells independently of SEC62 IRS (55.3% vs 93.3%; p = 0.024). CONCLUSIONS We are the first to describe the SEC62 expression and its correlation to clinicopathological parameters in mammary carcinoma. Our results suggest that SEC62 expression may serve as a prognostic marker for patients with invasive ductal breast cancer.
Collapse
Affiliation(s)
- Ferenc Zoltan Takacs
- Department of Obstetrics and Gynecology, University of Saarland, 66424, Homburg, Saar, Germany.
| | - Julia Caroline Radosa
- Department of Obstetrics and Gynecology, University of Saarland, 66424, Homburg, Saar, Germany
| | - Maximilian Linxweiler
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Saarland, 66424, Homburg, Saar, Germany
| | - Mariz Kasoha
- Department of Obstetrics and Gynecology, University of Saarland, 66424, Homburg, Saar, Germany.,Department of General and Surgical Pathology, University of Saarland, 66424, Homburg, Saar, Germany
| | - Rainer M Bohle
- Department of General and Surgical Pathology, University of Saarland, 66424, Homburg, Saar, Germany
| | - Florian Bochen
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Saarland, 66424, Homburg, Saar, Germany
| | - Clara Unger
- Department of Obstetrics and Gynecology, University of Saarland, 66424, Homburg, Saar, Germany
| | - Erich-Franz Solomayer
- Department of Obstetrics and Gynecology, University of Saarland, 66424, Homburg, Saar, Germany
| | - Bernard Schick
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Saarland, 66424, Homburg, Saar, Germany
| | - Ingolf Juhasz-Böss
- Department of Obstetrics and Gynecology, University of Saarland, 66424, Homburg, Saar, Germany
| |
Collapse
|
7
|
Takacs FZ, Linxweiler M, Solomayer EF, Kasoha M, Bochen F, Radosa JC, Unger C, Zimpfer A, Bohle RM, Schick B, Juhasz-Böss I. SEC62 – Marker für lymphatische- und Fernmetastasen sowie klinischen Verlauf bei Mammakarzinom. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- FZ Takacs
- Universität des Saarlandes, Klinik für Frauenheilkunde und Geburtshilfe, Homburg, Deutschland
| | - M Linxweiler
- Universität des Saarlandes, Klinik für Hals-, Nasen- und Ohrenheilkunde, Homburg, Deutschland
| | - EF Solomayer
- Universität des Saarlandes, Klinik für Frauenheilkunde und Geburtshilfe, Homburg, Deutschland
| | - M Kasoha
- Universität des Saarlandes, Klinik für Frauenheilkunde und Geburtshilfe, Homburg, Deutschland
- Universität des Saarlandes, Institut für Allgemeine und Spezielle Pathologie, Homburg, Deutschland
| | - F Bochen
- Universität des Saarlandes, Klinik für Hals-, Nasen- und Ohrenheilkunde, Homburg, Deutschland
| | - JC Radosa
- Universität des Saarlandes, Klinik für Frauenheilkunde und Geburtshilfe, Homburg, Deutschland
| | - C Unger
- Universität des Saarlandes, Klinik für Frauenheilkunde und Geburtshilfe, Homburg, Deutschland
| | - A Zimpfer
- Universität des Saarlandes, Institut für Allgemeine und Spezielle Pathologie, Homburg, Deutschland
| | - RM Bohle
- Universität des Saarlandes, Institut für Allgemeine und Spezielle Pathologie, Homburg, Deutschland
| | - B Schick
- Universität des Saarlandes, Klinik für Hals-, Nasen- und Ohrenheilkunde, Homburg, Deutschland
| | - I Juhasz-Böss
- Universität des Saarlandes, Klinik für Frauenheilkunde und Geburtshilfe, Homburg, Deutschland
| |
Collapse
|
8
|
Bal Z, Achenbach S, Unger C, Schindler F, Schneider R. P262Acute kidney injury and renal replacement therapy after resuscitated out-of-hospital cardiac arrest: risk factors and impact on prognosis in patients treated with mild therapeutic hypothermia. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Z Bal
- University of Erlangen-Nuremberg, Cardiology, Erlangen, Germany
| | - S Achenbach
- University of Erlangen-Nuremberg, Cardiology, Erlangen, Germany
| | - C Unger
- University of Erlangen-Nuremberg, Cardiology, Erlangen, Germany
| | - F Schindler
- University of Erlangen-Nuremberg, Cardiology, Erlangen, Germany
| | - R Schneider
- University of Erlangen-Nuremberg, Cardiology, Erlangen, Germany
| |
Collapse
|
9
|
Hildebrand A, Gronbach K, Unger C, Priwitzer M. Screeninguntersuchung auf Tuberkulose bei unbegleiteten minderjährigen Ausländern am Gesundheitsamt Stuttgart. Pneumologie 2018. [DOI: 10.1055/s-0037-1619139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
| | | | - C Unger
- Gesundheitsamt Rems-Murr-Kreis
| | | |
Collapse
|
10
|
Bretschneider C, Padilla PF, Das D, Jelovsek J, Unger C. 12: The impact of surgeon volume on perioperative adverse events in women undergoing minimally invasive hysterectomy for large uteri. Am J Obstet Gynecol 2018. [DOI: 10.1016/j.ajog.2017.12.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Davidson E, Woodburn K, AlHilli M, Unger C. 13: Perioperative adverse events in women undergoing concurrent urogynecologic and gynecologic oncology surgeries. Am J Obstet Gynecol 2018. [DOI: 10.1016/j.ajog.2017.12.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Kristeleit R, Lorusso D, Oaknin A, Safra T, Swisher E, Bondarenko I, Huzarski T, Klat J, Moiseyenko V, Póka R, Viola L, Tankersley C, Maloney L, Goble S, Unger C, Dowson A, Giordano H, Oza A. ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Kramer N, Schmöllerl J, Unger C, Nivarthi H, Rudisch A, Unterleuthner D, Scherzer M, Riedl A, Artaker M, Crncec I, Lenhardt D, Schwarz T, Prieler B, Han X, Hengstschläger M, Schüler J, Eferl R, Moriggl R, Sommergruber W, Dolznig H. Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. Oncogene 2017; 36:5460-5472. [DOI: 10.1038/onc.2017.144] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 02/15/2017] [Accepted: 04/14/2017] [Indexed: 02/07/2023]
|
14
|
Jallad K, Ridgeway B, Paraiso M, Gurland B, Unger C. 10: Long term outcomes following ventral rectopexy with sacrocolpopexy or hysteropexy for the treatment of concurrent rectal and pelvic organ prolapse. Am J Obstet Gynecol 2017. [DOI: 10.1016/j.ajog.2016.12.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Kasoha M, Solomayer EF, Unger C, Bohle RM, Zaharia C, Ezziddin S, Juhasz-Böss I. Prostate-Specific Membrane Antigen (PSMA) expression in breast cancer and its metastases. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
16
|
Kratz F, Ehling G, Kauffmann HM, Unger C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol 2016; 26:19-35. [PMID: 17334177 DOI: 10.1177/0960327107073825] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) is an albumin-binding prodrug of doxorubicin with acid-sensitive properties that demonstrates superior antitumor efficacy in murine tumor models, and has been evaluated in a phase I study. In order to establish the toxicity profile of this prodrug, acute and repeat-dose toxicity studies were performed with DOXO-EMCH in CD1-mice, Sprague-Dawley rats and Beagle dogs. Although the objective of the acute toxicity studies was not the determination of LD50 values, the LD50 of DOXO-EMCH was >60mg/kg doxorubicin equivalents in both male and female mice (the LD50 of doxorubicin in CD-1 mice is ~12 mg/kg). In Sprague-Dawley rats, the LD50 was 23.4 and 45.9 mg/kg doxorubicin equivalents for males and females, respectively. For comparison, the LD50 of doxorubicin in Sprague-Dawley rats is ~10.5 mg/kg. The major clinical sign noted following intravenous administration of DOXOEMCH in mice and rats was a dose-dependent peripheral neuropathy which, in general, developed as a delayed toxicity 1-3 weeks after application. The observed neurotoxicity has been well documented for Sprague-Dawley rats treated with doxorubicin at a dose of 5 and 10 mg/kg. In Beagle dogs, LD10 was not reached for DOXO-EMCH at 4.5 mg/kg doxorubicin equivalents. A four-cycle intravenous study with DOXO-EMCH at dose levels of 4×2.5, 5.0 or 7.5 mg/kg doxorubicin equivalents in rats revealed approximately three-fold less side effects on the hemolymphoreticular system when compared to 4×2.5 mg/kg doxorubicin dose, whereas effects on the testes/oligospermia seem to be comparable between both drugs at equitoxic dose. A No Observable Adverse Effect Level (NOAEL) for DOXO-EMCH of 4×2.5 mg/kg doxorubicin equivalents was established in this study. This dose is equivalent to the maximum tolerated dose (MTD) of doxorubicin in rats. In a two-cycle study over a period of 6 weeks in Beagle dogs (intravenous administration of DOXO-EMCH at dose levels of 1.5, 3.0 or 4.5 mg/kg doxorubicin equivalents), dose-related systemic histamine-like reactions within the first 3 hours after injection were noted in all treated groups. Only transient and temporary effects on hematology, urinary function, as well as on histopathology in mid- and/or high-dose animals, were observed. The low dose of 2×1.5 mg/kg was considered to be the NOAEL in this study, which is equivalent to twice the MTD of doxorubicin in Beagle dogs. In summary, the toxicity studies with DOXO-EMCH in mice, rats or dogs have not identified any other special toxicity when compared to the toxicity data for doxorubicin. Preclinical tolerance of DOXO-EMCH was higher in mice, rats and dogs compared to doxorubicin. A dose of 20 mg/m2 doxorubicin equivalents was recommended as the starting dose for a phase I study with DOXO-EMCH.
Collapse
Affiliation(s)
- F Kratz
- Tumor Biology Center, Department of Medical Oncology, Clinical Research, Breisacher Strasse 117, D-79106 Freiburg, Germany.
| | | | | | | |
Collapse
|
17
|
Affiliation(s)
- D Berkovic
- Medizinische Universitätsklinik, Abteilung Hämatologie/Onkologie, Göttingen, FRG
| | | | | | | |
Collapse
|
18
|
Reitz RC, Kötting J, Unger C, Eibl H. Comparison of the tissue distribution of hexadecylphosphocholine and erucylphosphocholine. Prog Exp Tumor Res 2015; 34:143-52. [PMID: 1438797 DOI: 10.1159/000420839] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- R C Reitz
- Max-Planck Institute for Biophysical Chemistry, FRG
| | | | | | | |
Collapse
|
19
|
Kötting J, Marschner NW, Neumüller W, Unger C, Eibl H. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog Exp Tumor Res 2015; 34:131-42. [PMID: 1438796 DOI: 10.1159/000420838] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- J Kötting
- Max-Planck-Institut für biophysikalische Chemie, Göttingen, FRG
| | | | | | | | | |
Collapse
|
20
|
Affiliation(s)
- P Kaufmann-Kolle
- Max-Planck-Institut für biophysikalische Chemie, Abteilung Membranbiophysik, Göttingen, FRG
| | | | | |
Collapse
|
21
|
Kötting J, Marschner NW, Unger C, Eibl H. Determination of alkylphosphocholines and of alkyl-glycero-phosphocholines in biological fluids and tissues. Prog Exp Tumor Res 2015; 34:6-11. [PMID: 1438804 DOI: 10.1159/000420826] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- J Kötting
- Max-Planck-Institut für biophysikalische Chemie, Göttingen, FRG
| | | | | | | |
Collapse
|
22
|
Hochhuth C, Doenecke D, Unger C, Eibl H. Early effects of hexadecylphosphocholine on gene expression in leukemia cell lines. Prog Exp Tumor Res 2015; 34:77-89. [PMID: 1438805 DOI: 10.1159/000420834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- C Hochhuth
- Medizinische Universitätsklinik, Abteilung Hämatologie/Onkologie, Göttingen, FRG
| | | | | | | |
Collapse
|
23
|
Affiliation(s)
- E A Fleer
- Medizinische Universitätsklinik, Abteilung Hämatologie/Onkologie, Göttingen, FRG
| | | | | | | |
Collapse
|
24
|
Unger C, Sindermann H, Peukert M, Hilgard P, Engel J, Eibl H. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog Exp Tumor Res 2015; 34:153-9. [PMID: 1438798 DOI: 10.1159/000420840] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- C Unger
- Department of Internal Medicine, University Hospital Göttingen, FRG
| | | | | | | | | | | |
Collapse
|
25
|
Vehmeyer K, Liersch T, Eibl H, Unger C. Hexadecylphosphocholine amplifies the effect of granulocyte colony-stimulating factor on differentiating hematopoietic progenitor cells. Prog Exp Tumor Res 2015; 34:69-76. [PMID: 1279741 DOI: 10.1159/000420833] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- K Vehmeyer
- Department of Internal Medicine, Göttingen, FRG
| | | | | | | |
Collapse
|
26
|
Unger C, Fleer EA, Kötting J, Neumüller W, Eibl H. Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines. Prog Exp Tumor Res 2015; 34:25-32. [PMID: 1438800 DOI: 10.1159/000420829] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- C Unger
- Medizinische Universitätsklinik, Abteilung Hämatologie/Onkologie, Göttingen, FRG
| | | | | | | | | |
Collapse
|
27
|
Wezel F, Novak D, Larribere L, Galach M, Unger C, Utikal J. 1006 Directed differentiation of human induced pluripotent stem cells (hiPS) for urothelial cell-based tissue-engineering therapies. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/s1569-9056(15)60994-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Jannasch M, Groeber F, Brattig NW, Unger C, Walles H, Hansmann J. Development and application of three-dimensional skin equivalents for the investigation of percutaneous worm invasion. Exp Parasitol 2015; 150:22-30. [PMID: 25592729 DOI: 10.1016/j.exppara.2015.01.005] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Revised: 12/05/2014] [Accepted: 01/07/2015] [Indexed: 01/26/2023]
Abstract
Investigation of percutaneous helminth infection is generally based on animal models or excised skin. As desirable replacement of animal experiments, tissue-engineered skin equivalents have recently been applied in microbial and viral in vitro infection models. In the present study, the applicability of tissue-engineered skin equivalents for the investigation of percutaneous helminth invasion was evaluated. Epidermal and a full-thickness skin equivalents that suit the requirements for helminth invasion studies were developed. Quantitative invasion assays were performed with the skin-invading larvae of the helminths Strongyloides ratti and Schistosoma mansoni. Both skin equivalents provided a physical barrier to larval invasion of the nematode S. ratti, while these larvae could invade and permeate a cell-free collagen scaffold and ex vivo epidermis. In contrast, the epidermal and full-thickness skin equivalents exhibited a human host-specific susceptibility to larvae of trematode S. mansoni, which could well penetrate. Invasion of S. mansoni in cell-free collagen scaffold was lowest for all experimental conditions. Thus, reconstructed epidermis and full-thickness skin equivalents confirmed a high degree of accordance to native tissue. Additionally, not only tailless schistosomula but also cercariae could permeate the skin equivalents, and thus, delayed tail loss hypothesis was supported. The present study indicates that the limitations in predictive infection test systems for human-pathogenic invading helminths can be overcome by tissue-engineered in vitro skin equivalents allowing a substitution of the human skin for analysis of the interaction between parasites and their hosts' tissues. This novel tissue-engineered technology accomplishes the endeavor to save animal lives.
Collapse
Affiliation(s)
- M Jannasch
- Chair Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, Wuerzburg, Germany
| | - F Groeber
- Department of Cell and Tissue Engineering, Fraunhofer Institute of Interfacial Engineering and Biotechnology (IGB), Stuttgart, Germany
| | - N W Brattig
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - C Unger
- Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany
| | - H Walles
- Chair Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, Wuerzburg, Germany
| | - J Hansmann
- Chair Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.
| |
Collapse
|
29
|
McKinnon R, Binder M, Zupkó I, Afonyushkin T, Lajter I, Vasas A, de Martin R, Unger C, Dolznig H, Diaz R, Frisch R, Passreiter CM, Krupitza G, Hohmann J, Kopp B, Bochkov VN. Pharmacological insight into the anti-inflammatory activity of sesquiterpene lactones from Neurolaena lobata (L.) R.Br. ex Cass. Phytomedicine 2014; 21:1695-1701. [PMID: 25442279 DOI: 10.1016/j.phymed.2014.07.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 07/23/2014] [Accepted: 07/29/2014] [Indexed: 06/04/2023]
Abstract
PURPOSE Neurolaena lobata is a Caribbean medicinal plant used for the treatment of several conditions including inflammation. Recent data regarding potent anti-inflammatory activity of the plant and isolated sesquiterpene lactones raised our interest in further pharmacological studies. The present work aimed at providing a mechanistic insight into the anti-inflammatory activity of N. lobata and eight isolated sesquiterpene lactones, as well as a structure-activity relationship and in vivo anti-inflammatory data. METHODS The effect of the extract and its compounds on the generation of pro-inflammatory proteins was assessed in vitro in endothelial and monocytic cells by enzyme-linked immunosorbent assay. Their potential to modulate the expression of inflammatory genes was further studied at the mRNA level. In vivo anti-inflammatory activity of the chemically characterized extract was evaluated using carrageenan-induced paw edema model in rats. RESULTS The compounds and extract inhibited LPS- and TNF-α-induced upregulation of the pro-inflammatory molecules E-selectin and interleukin-8 in HUVECtert and THP-1 cells. LPS-induced elevation of mRNA encoding for E-selectin and interleukin-8 was also suppressed. Furthermore, the extract inhibited the development of acute inflammation in rats. CONCLUSIONS Sesquiterpene lactones from N. lobata interfered with the induction of inflammatory cell adhesion molecules and chemokines in cells stimulated with bacterial products and cytokines. Structure-activity analysis revealed the importance of the double bond at C-4-C-5 and C-2-C-3 and the acetyl group at C-9 for the anti-inflammatory activity. The effect was confirmed in vivo, which raises further interest in the therapeutic potential of the compounds for the treatment of inflammatory diseases.
Collapse
Affiliation(s)
- R McKinnon
- Department of Pharmacognosy, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria.
| | - M Binder
- Department of Vascular Biology and Thrombosis Research, Center of Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| | - I Zupkó
- Department of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
| | - T Afonyushkin
- Department of Vascular Biology and Thrombosis Research, Center of Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| | - I Lajter
- Department of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
| | - A Vasas
- Department of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
| | - R de Martin
- Department of Vascular Biology and Thrombosis Research, Center of Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| | - C Unger
- Institute of Medical Genetics, Medical University of Vienna, Währinger Strasse 10, A-1090 Vienna, Austria
| | - H Dolznig
- Institute of Medical Genetics, Medical University of Vienna, Währinger Strasse 10, A-1090 Vienna, Austria
| | - R Diaz
- Institute of Ethnobiology, Playa Diana, San José/Petén, Guatemala
| | - R Frisch
- Institute of Ethnobiology, Playa Diana, San José/Petén, Guatemala
| | - C M Passreiter
- Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine-University Düsseldorf, Universitätsstrasse 1, D-40225 Düsseldorf, Germany
| | - G Krupitza
- Clinical Institute of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
| | - J Hohmann
- Department of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
| | - B Kopp
- Department of Pharmacognosy, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria
| | - V N Bochkov
- Department of Vascular Biology and Thrombosis Research, Center of Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| |
Collapse
|
30
|
Rupp C, Scherzer M, Rudisch A, Unger C, Haslinger C, Schweifer N, Artaker M, Nivarthi H, Moriggl R, Hengstschläger M, Kerjaschki D, Sommergruber W, Dolznig H, Garin-Chesa P. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. Oncogene 2014; 34:815-25. [PMID: 24632618 DOI: 10.1038/onc.2014.18] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2013] [Revised: 12/26/2013] [Accepted: 01/31/2014] [Indexed: 02/07/2023]
Abstract
The activated tumor stroma participates in many processes that control tumorigenesis, including tumor cell growth, invasion and metastasis. Cancer-associated fibroblasts (CAFs) represent the major cellular component of the stroma and are the main source for connective tissue components of the extracellular matrix and various classes of proteolytic enzymes. The signaling pathways involved in the interactions between tumor and stromal cells and the molecular characteristics that distinguish normal 'resting' fibroblasts from cancer-associated or '-activated' fibroblasts remain poorly defined. Recent studies emphasized the prognostic and therapeutic significance of CAF-related molecular signatures and a number of those genes have been shown to serve as putative therapeutic targets. We have used immuno-laser capture microdissection and whole-genome Affymetrix GeneChip analysis to obtain transcriptional signatures from the activated tumor stroma of colon carcinomas that were compared with normal resting colonic fibroblasts. Several members of the Wnt-signaling pathway and gene sets related to hypoxia, epithelial-to-mesenchymal transition (EMT) and transforming growth factor-β (TGFβ) pathway activation were induced in CAFs. The putative TGFβ-target IGFBP7 was identified as a tumor stroma marker of epithelial cancers and as a tumor antigen in mesenchyme-derived sarcomas. We show here that in contrast to its tumor-suppressor function in epithelial cells, IGFPB7 can promote anchorage-independent growth in malignant mesenchymal cells and in epithelial cells with an EMT phenotype when IGFBP7 is expressed by the tumor cells themselves and can induce colony formation in colon cancer cells co-cultured with IGFBP7-expressing CAFs by a paracrine tumor-stroma interaction.
Collapse
Affiliation(s)
- C Rupp
- Clinical Institute for Pathology, Medical University of Vienna, Vienna, Austria
| | - M Scherzer
- Institute of Medical Genetics, Center of Pathobiology and Genetics, Medical University of Vienna, Vienna, Austria
| | - A Rudisch
- Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
| | - C Unger
- Institute of Medical Genetics, Center of Pathobiology and Genetics, Medical University of Vienna, Vienna, Austria
| | - C Haslinger
- Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
| | - N Schweifer
- Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
| | - M Artaker
- Max F. Perutz Laboratories, Medical University of Vienna, Vienna, Austria
| | - H Nivarthi
- Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
| | - R Moriggl
- Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
| | - M Hengstschläger
- Institute of Medical Genetics, Center of Pathobiology and Genetics, Medical University of Vienna, Vienna, Austria
| | - D Kerjaschki
- Clinical Institute for Pathology, Medical University of Vienna, Vienna, Austria
| | | | - H Dolznig
- Institute of Medical Genetics, Center of Pathobiology and Genetics, Medical University of Vienna, Vienna, Austria
| | - P Garin-Chesa
- 1] Clinical Institute for Pathology, Medical University of Vienna, Vienna, Austria [2] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
| |
Collapse
|
31
|
Veitshans S, Willems P, Philipp A, Merk T, Muradov A, Stamatopoulou A, Hetzel M, Priwitzer M, Unger C. MDR-Tuberkulose in der Schwangerschaft: Konsequenzen für die Therapie, den Geburtsmodus und die Prävention beim Kind – Ein Fallbericht. Pneumologie 2014. [DOI: 10.1055/s-0034-1367893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
|
33
|
|
34
|
Koch L, Gruene M, Unger C, Chichkov B. Laser assisted cell printing. Curr Pharm Biotechnol 2013; 14:91-97. [PMID: 23570054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Computer assisted biofabrication of fully functional living tissue for regenerative medicine involves generation of complex three-dimensional constructs consisting of living cells and biomaterials. Laser BioPrinting (LaBP) based on laser-induced forward-transfer provides unique possibilities for the deposition of different living cells and biomaterials in a well-defined 3D structure. LaBP can be applied to generate scaffold-free 3D cell systems through a layer-by-layer technique by combining cell solutions with materials that are able to form stable gels. Also, it is used to precisely populate scaffolds with different cells and different cell densities. It was proven that printed cells are not affected by the laser printing procedure and that a differentiation of printed stem cells is not induced. Thus, LaBP is demonstrated as a promising tool for the ex vivo generation of tissue replacements.
Collapse
Affiliation(s)
- L Koch
- Laser Zentrum Hannover e.V., Hannover, Germany
| | | | | | | |
Collapse
|
35
|
Unger C, Lück C. Inhibitory effects of silver ions on Legionella pneumophila grown on agar, intracellular in Acanthamoeba castellanii and in artificial biofilms. J Appl Microbiol 2012; 112:1212-9. [PMID: 22413947 DOI: 10.1111/j.1365-2672.2012.05285.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIMS We undertook a series of experiments to investigate the susceptibility of Legionella pneumophila grown under extracellular and intracellular conditions and other water-related bacteria to silver ions. METHODS AND RESULTS In this study, the antimicrobial effect of silver ions to intra- and extra-cellular grown Legionella bacteria was investigated. The minimal inhibitory concentration (MIC) after 24 h exposure, leading to a 5 log reduction, was c. 64 μg l(-1) AgNO(3) for extracellular grown Legionella and other tested Gram-positive and Gram-negative bacteria. In contrast, the MIC for intracellularly grown Legionella was up to 4096 μg l(-1) AgNO(3) after 24 h. Furthermore, the heterotrophic bacteria grown within a biofilm model were killed at a concentration of 4-16 μg l(-1) AgNO(3). In contrast, biofilm-associated Legionella were less sensitive (MIC 128-512 μg l(-1) AgNO(3)). CONCLUSION Intracellularly and biofilm-grown legionellae are less sensitive against silver compared with agar-grown bacteria. SIGNIFICANCE AND IMPACT OF THE STUDY The reduced sensitivity of Legionella grown in amoebae might explain why the effect of silver decontamination requires an extended exposure in field trials.
Collapse
Affiliation(s)
- C Unger
- Institute of Medical Microbiology and Hygiene, Faculty of Medicine 'Carl Gustav Carus', University of Technology, Dresden, Germany
| | | |
Collapse
|
36
|
Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol 2012; 19:e28-35. [PMID: 22328845 PMCID: PMC3267594 DOI: 10.3747/co.19.866] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND This open-label phase i study with an accelerated titration design was performed to determine the maximum tolerated dose of BI 2536, a potent, highly selective small-molecule polo-like kinase 1 (Plk1) inhibitor. METHODS Patients with advanced solid tumours received a single 60-minute intravenous infusion of BI 2536 (50-70 mg) on days 1-3 of each 21-day treatment course. Recipients without disease progression or untenable toxicity could receive additional treatment courses. The maximum tolerated dose was determined based on dose-limiting toxicities. Other assessments included safety, pharmacokinetic profile, and antitumour activity according to the Response Evaluation Criteria in Solid Tumors. RESULTS The study enrolled 21 patients. The maximum tolerated dose for BI 2536 was determined to be 60 mg for the study schedule. Dose-limiting toxicities included hematologic events, hypertension, elevated liver enzymes, and fatigue. The most frequently reported drug-related adverse events were mild-to-moderate fatigue, leukopenia, constipation, nausea, mucosal inflammation, anorexia, and alopecia. The pharmacokinetics of BI 2536 were linear within the dose range tested. Plasma concentration profiles exhibited multi-compartmental pharmacokinetic behaviour, with a terminal elimination half-life of 20-30 hours. CONCLUSIONS In the present study, BI 2536 showed an acceptable safety profile warranting further investigation of Plk1 inhibitors in this patient population.
Collapse
Affiliation(s)
- A. Frost
- Klinik für Internistische Onkologie (KIO), Freiburg im Breisgau, Germany
| | - K. Mross
- Klinik für Internistische Onkologie (KIO), Freiburg im Breisgau, Germany
| | - S. Steinbild
- Klinik für Internistische Onkologie (KIO), Freiburg im Breisgau, Germany
| | - S. Hedbom
- Klinik für Internistische Onkologie (KIO), Freiburg im Breisgau, Germany
| | - C. Unger
- Klinik für Internistische Onkologie (KIO), Freiburg im Breisgau, Germany
| | - R. Kaiser
- Boehringer Ingelheim Pharma, Biberach an der Riss, Germany
| | | | - G. Munzert
- Boehringer Ingelheim Pharma, Biberach an der Riss, Germany
| |
Collapse
|
37
|
Unger C, Mueller C, Bausch MP, Krzemieniecki K, Ochenduszko S, Wilk B, Jaeger E, Al-Batran S. A phase I schedule optimization study of pegylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-l-norleucine (DON) in patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Gruene M, Pflaum M, Deiwick A, Koch L, Schlie S, Unger C, Wilhelmi M, Haverich A, Chichkov BN. Adipogenic differentiation of laser-printed 3D tissue grafts consisting of human adipose-derived stem cells. Biofabrication 2011; 3:015005. [PMID: 21358040 DOI: 10.1088/1758-5082/3/1/015005] [Citation(s) in RCA: 117] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Laser-assisted bioprinting (LaBP) allows the realization of computer-generated 3D tissue grafts consisting of cells embedded in a hydrogel environment. In this study, human adipose-derived stem cells (hASCs) were printed in a free-scalable 3D grid pattern by means of LaBP. We demonstrate that neither the proliferation ability nor the differentiation behaviour of the stem cells was affected by the LaBP procedure. Furthermore, the 3D grafts were differentiated down the adipogenic lineage pathway for 10 days. We verify by quantitative assessments of adipogenic markers that the 3D grafts resemble cell lineages present in natural adipose tissue. Additionally, we provide the proof that even pre-differentiated hASCs could be utilized for the generation of 3D tissue grafts. These results indicate that the biofabrication of living grafts resembling their complex native origin is within reach.
Collapse
Affiliation(s)
- M Gruene
- Nanotechnology Department, Laser Zentrum Hannover e.V., Hollerithallee 8, Hannover, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Müller D, Augustin M, Banik N, Baumann W, Bestehorn K, Kieschke J, Lefering R, Maier B, Mathis S, Rustenbach S, Sauerland S, Semler S, Stausberg J, Sturm H, Unger C, Neugebauer E. Memorandum Register für die Versorgungsforschung *. Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1268484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- D. Müller
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - M. Augustin
- Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen, Universitätsklinikum Hamburg-Eppendorf
| | - N. Banik
- GlaxoSmithKline GmbH & Co. KG, München
| | - W. Baumann
- Wissenschaftliches Institut der Niedergelassenen Hämatologen und Onkologen GmbH (WINHO), Köln
| | | | - J. Kieschke
- Berliner Herzinfarktregister, Innovationszentrum Technologien für Gesundheit und Ernährung, TU Berlin
| | - R. Lefering
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - B. Maier
- Berliner Herzinfarktregister, Innovationszentrum Technologien für Gesundheit und Ernährung, TU Berlin
| | - S. Mathis
- Ludwig Boltzmann Institut Health Technology Assessment, Wien
| | - S. Rustenbach
- Universitätsklinikum Hamburg-Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen, Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm)
| | - S. Sauerland
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - S. Semler
- Telematikplattform für Medizinische Forschungsnetze e. V. (TMF), Berlin
| | - J. Stausberg
- Telematikplattform für Medizinische Forschungsnetze e. V. (TMF), Berlin
| | - H. Sturm
- Südwestdeutsches Tumorzentrum, Universitätsklinikum Tübingen; Schwenninger BKK, Schwenningen
| | - C. Unger
- Epidemiologisches Krebsregister Niedersachsen, Hannover
| | - E. Neugebauer
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | | |
Collapse
|
40
|
Elsadek B, Graeser R, Esser N, Schäfer-Obodozie C, Tsurumi C, Abu Ajaj K, Warnecke A, Unger C, Saleem T, Kratz F. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP). Prostate Cancer Prostatic Dis 2010; 14:14-21. [PMID: 21042336 DOI: 10.1038/pcan.2010.43] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
PSA, which is overexpressed in prostate carcinoma, represents a molecular target for selectively releasing an anticancer agent from a prodrug formulation. In this study, we report on the in vivo antitumor efficacy of an efficacious albumin-binding prodrug of doxorubicin (PSA9) that incorporates p-aminobenzyloxycarbonyl (PABC) as a self-immolative spacer in addition to the heptapeptide, Arg-Ser-Ser-Tyr-Tyr-Ser-Leu, which serves as a substrate for PSA. The prodrug is cleaved very efficiently by PSA releasing H-Ser-Leu-PABC-doxorubicin and subsequently doxorubicin in PSA-positive cell lysates and prostate tumor homogenates as the final cleavage product. PSA9 at 3 × 6 mg kg(-1) doxorubicin equivalents (intravenous) was compared with conventional doxorubicin at equitoxic doses (at 3 × 3 mg kg(-1); intravenous) in an orthotopic mouse model of prostate cancer using LNCaP lentiviral luciferase-neomycin cells transduced with luciferase. Whereas doxorubicin did not show any efficacy against the primary tumor or metastases, the prodrug reduced the primary tumor by 30-50% and circulating PSA levels, and in addition, showed a pronounced reduction in lung and bone metastases by ∼77% and ∼96%, respectively, and a positive trend regarding the activity against liver and lymph-node metastases compared with control and doxorubicin-treated animals. The incorporation of PABC as a self-immolative spacer together with a PSA substrate demonstrates superior antitumor effects over doxorubicin attributed to an efficient cleavage by PSA releasing doxorubicin as the final active agent in prostate tumor homogenates. Using this approach for developing effective prodrugs against prostate cancer, is worthy of further preclinical optimization.
Collapse
Affiliation(s)
- B Elsadek
- Division of Macromolecular Prodrugs, Tumor Biology Center, Freiburg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Unger C, Maas S, Hundack L, Schreiber J. Narrow Band Imaging in der bronchoskopischen Diagnostik des Bronchialkarzinoms. Pneumologie 2010. [DOI: 10.1055/s-2010-1268897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Müller D, Augustin M, Banik N, Baumann W, Bestehorn K, Kieschke J, Lefering R, Maier B, Mathis S, Rustenbach S, Sauerland S, Semler S, Stausberg J, Sturm H, Unger C, Neugebauer E. Memorandum Register für die Versorgungsforschung *. Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1267233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- D. Müller
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - M. Augustin
- Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen, Universitätsklinikum Hamburg-Eppendorf
| | - N. Banik
- GlaxoSmithKline GmbH & Co. KG, München
| | - W. Baumann
- Wissenschaftliches Institut der Niedergelassenen Hämatologen und Onkologen GmbH (WINHO), Köln
| | | | - J. Kieschke
- Berliner Herzinfarktregister, Innovationszentrum Technologien für Gesundheit und Ernährung, TU Berlin
| | - R. Lefering
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - B. Maier
- Berliner Herzinfarktregister, Innovationszentrum Technologien für Gesundheit und Ernährung, TU Berlin
| | - S. Mathis
- Ludwig Boltzmann Institut Health Technology Assessment, Wien
| | - S. Rustenbach
- Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen, Universitätsklinikum Hamburg-Eppendorf
| | - S. Sauerland
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - S. Semler
- Telematikplattform für Medizinische Forschungsnetze e. V. (TMF), Berlin
| | - J. Stausberg
- Telematikplattform für Medizinische Forschungsnetze e. V. (TMF), Berlin
| | - H. Sturm
- Südwestdeutsches Tumorzentrum, Universitätsklinikum Tübingen; Schwenninger BKK, Schwenningen
| | - C. Unger
- Epidemiologisches Krebsregister Niedersachsen, Hannover
| | - E. Neugebauer
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | | |
Collapse
|
43
|
Müller D, Augustin M, Banik N, Baumann W, Bestehorn K, Kieschke J, Lefering R, Maier B, Mathis S, Rustenbach SJ, Sauerland S, Semler SC, Stausberg J, Sturm H, Unger C, Neugebauer EAM. [Memorandum registry for health services research]. Gesundheitswesen 2010; 72:824-39. [PMID: 20872343 DOI: 10.1055/s-0030-1263132] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
On August 30, 2010, the German Network for Health Services Research [Deutsches Netzwerk Versorgungsforschung e. V. (DNVF e. V.)] approved the Memorandum III "Methods for Health Services Research", supported by their member societies mentioned as authors and published in this Journal [Gesundheitswesen 2010; 72: 739-748]. Registries in Health Services Research vary in their aims and research questions as well as in their designs, methods of data collection, and statistical analyses. This paper aims to provide both a methodological guideline for developers to ensure a high quality of a planned registry and, to provide an instrument for users of data from registries to assess their overall quality. First, the paper provides a definition of registries and presents an overview of objectives in Health Services Research where registries can be useful. Second, several areas of methodological importance for the development of registries are presented. This includes the different phases of a registry (i. e., conceptual and preliminary design, implementation), technical organisation of a registry, statistical analysis, reporting of results, data protection, and ethical/legal aspects. From these areas, several criteria are deduced to allow the assessment of the quality of a registry. Finally, a checklist to assess a registry's quality is presented.
Collapse
Affiliation(s)
- D Müller
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - M Augustin
- Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen, Universitätsklinikum Hamburg-Eppendorf
| | - N Banik
- GlaxoSmithKline GmbH & Co. KG, München
| | - W Baumann
- Wissenschaftliches Institut der Niedergelassenen Hämatologen und Onkologen GmbH (WINHO), Köln
| | | | - J Kieschke
- Berliner Herzinfarktregister, Innovationszentrum Technologien für Gesundheit und Ernährung, TU Berlin
| | - R Lefering
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - B Maier
- Berliner Herzinfarktregister, Innovationszentrum Technologien für Gesundheit und Ernährung, TU Berlin
| | - S Mathis
- Ludwig Boltzmann Institut Health Technology Assessment, Wien
| | | | - S Sauerland
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| | - S C Semler
- Telematikplattform für Medizinische Forschungsnetze e. V. (TMF), Berlin
| | - J Stausberg
- Telematikplattform für Medizinische Forschungsnetze e. V. (TMF), Berlin,Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München
| | - H Sturm
- Südwestdeutsches Tumorzentrum, Universitätsklinikum Tübingen; Schwenninger BKK, Schwenningen
| | - C Unger
- Epidemiologisches Krebsregister Niedersachsen, Hannover,Niedersächsisches Landesgesundheitsamt, Hannover
| | - E A M Neugebauer
- Institut für Forschung in der Operativen Medizin, Universität Witten-Herdecke
| |
Collapse
|
44
|
Nennecke A, Emrich K, Geiss K, Holleczek B, Kraywinkel K, Luttmann S, Unger C. Validierung des Vitalstatus in der epidemiologischen Krebsregistrierung. Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1266438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
45
|
Unger C, Becher R, Rieche K, Wander H, Friedrich G, Edler L. Daily Oral Miltefosine (Hexadecylphosphocholine) in Patients with Advanced Breast Cancer: A Phase II Study. Oncol Res Treat 2009. [DOI: 10.1159/000218271] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
46
|
Graeser R, Esser N, Unger H, Fichtner I, Zhu A, Unger C, Kratz F. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs 2009; 28:14-9. [PMID: 19148580 DOI: 10.1007/s10637-008-9208-2] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2008] [Accepted: 12/08/2008] [Indexed: 10/21/2022]
Abstract
The (6-maleimidocaproyl)hydrazone derivative of doxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin with acid-sensitive properties that is being assessed clinically. The prodrug binds rapidly to circulating serum albumin and releases doxorubicin selectively at the tumor site. This novel mechanism may provide enhanced antitumor activity of doxorubicin while improving the overall toxicity profile. Preclinically, INNO-206 has shown superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models. In this work, we compared the antitumor activity of INNO-206 and doxorubicin at their respective maximum tolerated doses in three additional xenograft models (breast carcinoma 3366, ovarian carcinoma A2780, and small cell lung cancer H209) as well as in an orthotopic pancreas carcinoma model (AsPC-1). INNO-206 showed more potent antitumor efficacy than free doxorubicin in all tumor models and is thus a promising clinical candidate for treating a broad range of solid tumors.
Collapse
Affiliation(s)
- R Graeser
- Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Strasse 117, 79106, Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|
47
|
Waldburg N, Unger C, Schreiber J. Klinische und endoskopische Manifestation von hochdifferenzierten neuroendokrinen Tumoren – Karzinoiden – der Lunge. Pneumologie 2008. [DOI: 10.1055/s-0028-1096585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Unger C, Reibe A, Schreiber J. Rezidivierende Bronchitiden infolge einer Laser-Drucker Exposition? Pneumologie 2008. [DOI: 10.1055/s-0028-1096583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Martin-Ibañez R, Unger C, Strömberg A, Baker D, Canals JM, Hovatta O. Novel cryopreservation method for dissociated human embryonic stem cells in the presence of a ROCK inhibitor. Hum Reprod 2008; 23:2744-54. [PMID: 18716037 DOI: 10.1093/humrep/den316] [Citation(s) in RCA: 99] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Human embryonic stem cells (hESCs) have potential use in clinical therapy and regenerative medicine. One of the major challenges regarding the application of these cells is the development of an efficient cryopreservation protocol, since current methods, which include slow-freezing-rapid thawing and vitrification of colonies in suspension, present poor viability and high differentiation rates. Dissociated hESC suspensions do not survive cryopreservation because they are susceptible to apoptosis upon cell detachment and dissociation. A selective Rho-associated kinase (ROCK) inhibitor has been reported to increase the survival of dissociated hESCs and their cloning efficiency. METHODS AND RESULTS Here, we describe a novel method for dissociated hESCs cryopreservation in the presence of the ROCK inhibitor Y-27632. The addition of this inhibitor to the freezing and post-thawing medium significantly increased the survival rate and efficiency of colony formation. Moreover, the hESC colonies obtained after the cryopreservation in the presence of the ROCK inhibitor showed a very low rate of differentiation and a reduced time of recovery. After prolonged culture of frozen-thawed dissociated hESCs, the characteristic properties of pluripotent cells were observed, including normal karyotype, morphological features, marker expression (SSEA-4, TRA-1-60, TRA-1-81 and Oct-4) and the potential to differentiate into derivatives of all three germ layers after embryoid bodies formation. CONCLUSION This novel method for the cryopreservation of dissociated hESCs may reduce the time required to amplify frozen stocks, and facilitate not only the storage of large numbers of hESCs but also the widespread use of these cells in regenerative medicine.
Collapse
Affiliation(s)
- R Martin-Ibañez
- Departament de Biologia Cellular, Facultat de Medicina, IDIBAPS, Universitat de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
50
|
Langenberg M, van Herpen CM, De Bono JS, Unger C, Schellens JH, Hoekman K, Blum HE, Le Maulf F, Fielding A, Voest EE. Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3555] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|